Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 16, 2007AJP Gastrointestinal and Liver Physiology

Endocannabinoids and Liver Disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSören SiegmundBrigham and Women's HospitalRSRobert F. SchwabeColumbia University Irving Medical Center

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Siegmund et al. (2007) studied this question.

synapsesocial.com/papers/6a82fd3e86395db871b37ccdhttps://doi.org/10.1152/ajpgi.00456.2007
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Vasodilator mRNA levels are increased in the livers of portal hypertensive NO‐synthase 3‐deficient mice2004 · 24 citations
  2. 2Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity2005 · 987 citations